Literature DB >> 9881861

Preservation of cholinergic activity and prevention of neuron death by CEP-1347/KT-7515 following excitotoxic injury of the nucleus basalis magnocellularis.

M S Saporito1, E R Brown, S Carswell, A M DiCamillo, M S Miller, C Murakata, N T Neff, J L Vaught, F A Haun.   

Abstract

We have identified a class of small organic molecules, derived from the indolocarbazole K-252a, that promote the survival of cultured neurons. However, many of these indolocarbazoles inhibit protein kinase C and neurotrophin-activated tyrosine kinase receptors. These kinase inhibitory activities may limit the utility of these compounds for neurological disorders. A bis-ethyl-thiomethyl analogue of K-252a, CEP-1347/KT-7515, has been identified that lacks protein kinase C and tyrosine kinase receptor inhibitory activities, yet retains the ability to promote survival of cultured neurons, including cholinergic neurons derived from the basal forebrain. In the present studies, CEP-1347/KT-7515 was assessed for neurotrophic activity on basal forebrain neurons of in vivo rats following excitotoxic insult. Ibotenate infusion into the nucleus basalis magnocellularis reduced levels of choline acetyltransferase activity in the cortex, as well as reduced numbers of choline acetyltransferase-immunoreactive and retrogradely (FluoroGold)-labelled cortically-projecting neurons in the nucleus basalis. Systemically administered CEP-1347/KT-7515 attenuated the loss of cortical choline acetyltransferase activity and the loss of the number of choline acetyltransferase-immunoreactive and retrogradely-labelled FluoroGold neurons in the nucleus basalis. Moreover, CEP-1347/KT-7515 ameliorated the loss of cortical choline acetyltransferase if administration was initiated one day, but not seven days post-lesion. Together, these results demonstrate that CEP-1347/KT-7515 protects damaged cortically-projecting basal forebrain neurons from degeneration. Thus, CEP-1347/KT-7515 may have therapeutic potential in neurodegenerative diseases, such as Alzheimer's disease, in which basal forebrain cholinergic neurons degenerate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9881861     DOI: 10.1016/s0306-4522(98)00059-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  9 in total

Review 1.  Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease.

Authors:  Robert E Burke
Journal:  Pharmacol Ther       Date:  2007-02-27       Impact factor: 12.310

Review 2.  Targeting protein kinases in central nervous system disorders.

Authors:  Laura K Chico; Linda J Van Eldik; D Martin Watterson
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

3.  Combination Therapies for Traumatic Brain Injury: Retrospective Considerations.

Authors:  Susan Margulies; Gail Anderson; Fahim Atif; Jerome Badaut; Robert Clark; Philip Empey; Maria Guseva; Michael Hoane; Jimmy Huh; Jim Pauly; Ramesh Raghupathi; Stephen Scheff; Donald Stein; Huiling Tang; Mona Hicks
Journal:  J Neurotrauma       Date:  2015-08-06       Impact factor: 5.269

4.  Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation.

Authors:  U Pirvola; L Xing-Qun; J Virkkala; M Saarma; C Murakata; A M Camoratto; K M Walton; J Ylikoski
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

5.  The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis.

Authors:  Z Xu; A C Maroney; P Dobrzanski; N V Kukekov; L A Greene
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

6.  Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway.

Authors:  Julie Lotharius; Jeppe Falsig; Johan van Beek; Sarah Payne; Ralf Dringen; Patrik Brundin; Marcel Leist
Journal:  J Neurosci       Date:  2005-07-06       Impact factor: 6.167

7.  Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.

Authors:  Qing Ma; Harris A Gelbard; Sanjay B Maggirwar; Stephen Dewhurst; Howard E Gendelman; Derick R Peterson; Robin DiFrancesco; Jill S Hochreiter; Gene D Morse; Giovanni Schifitto
Journal:  J Neurovirol       Date:  2013-06-05       Impact factor: 2.643

8.  Overexpression of C-terminal fragment of glutamate receptor 6 prevents neuronal injury in kainate-induced seizure via disassembly of GluR6-PSD-95-MLK3 signaling module.

Authors:  Jie Mou; Xiaomei Liu; Dongsheng Pei
Journal:  Neural Regen Res       Date:  2014-12-01       Impact factor: 5.135

9.  Proteolytic fragments of laminin promote excitotoxic neurodegeneration by up-regulation of the KA1 subunit of the kainate receptor.

Authors:  Zu-Lin Chen; Huaxu Yu; Wei-Ming Yu; Robert Pawlak; Sidney Strickland
Journal:  J Cell Biol       Date:  2008-12-29       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.